Aliases:This biomarker is also known as:
- beta-chemokine RANTES,
- small inducible cytokine A5 (RANTES),
- chemokine (C-C motif) ligand 5,
- small-inducible cytokine A5,
- Small-inducible cytokine A5,
- T cell-specific protein P228,
- t cell-specific protein P228,
- C-C motif chemokine 5,
- T-cell specific protein p288,
- eosinophil chemotactic cytokine,
- regulated upon activation, normally T-expressed, and presumably secreted,
- small inducible cytokine subfamily A (Cys-Cys), member 5,
- T-cell-specific protein RANTES,
- Eosinophil chemotactic cytokine,
From NCBI Gene: This gene is one of several chemokine genes clustered on the q-arm of chromosome 17. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of the N-terminal cysteine residues of the mature peptide. This chemokine, a member of the CC subfamily, functions as a chemoattractant for blood monocytes, memory T helper cells and eosinophils. It causes the release of histamine from basophils and activates eosinophils. This cytokine is one of the major HIV-suppressive factors produced by CD8+ cells. It functions as one of the natural ligands for the chemokine receptor chemokine (C-C motif) receptor 5 (CCR5), and it suppresses in vitro replication of the R5 strains of HIV-1, which use CCR5 as a coreceptor. Alternative splicing results in multiple transcript variants that encode different isoforms. [provided by RefSeq, Jul 2013]
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
The chemokine CCL5 (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, has been implicated in the progression of breast cancer.
CCL5 (RANTES) was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.